Benchmark Holdings plc announce that it has been granted a variation to its Marketing Authorisation ("MA") for Ectosan® Vet from the Norwegian Medicines Agency ("NoMA"). This variation to the MA enables the re-use of the treatment water for a second batch of fish, subject to water quality being maintained to the satisfaction of the prescribing veterinarian, therefore increasing the efficiency of treatments. This means a producer will be able to treat a salmon farm more efficiently with a solution that delivers more than 99% efficacy, promotes animal welfare, reduces mortality and protects the environment - driving sustainability in the industry.

This MA variation represents a further important step towards goal of optimising the efficiency of sea lice solution, and further trials are ongoing to support multiple re-use of treatment water.